Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of inarigivir soproxil in non-cirrhotic HBeAg-negative chronic hepatitis B patients on or stopping nucleos(t)ide analogues
2019-000896-17Phase 2Completed
- Sponsor
- Spring Bank Pharmaceuticals, Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of inarigivir soproxil in Chronic Hepatitis B (CHB), sponsored by Spring Bank Pharmaceuticals, Inc. Primary endpoints: Safety of inarigivir soproxil and Antiviral efficacy of inarigivir soproxil. Started Sep 2020; status: completed.
02
Drugs
inarigivir soproxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-000896-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000896-17.